FTB Advisors Inc. reduced its position in Allergan PLC. (NYSE: AGN) by 1.8% throughout the 2nd quarter, inning accordance with the business in its most current Kind 13F filing with the Securities & & Exchange Commission. The firm owned 20,749 shares of the business's stock after offering 374 shares during the duration. FTB Advisors Inc.'s holdings in Allergan PLC. deserved $5,044,000 at the end of the most current quarter.
Other hedge funds have also recently contributed to or decreased their stakes in the business. Pathstone Household Workplace LLC raised its holdings in shares of Allergan PLC. by 3,327.3% throughout the 2nd quarter. Pathstone Family Workplace LLC now owns 377 shares of the company's stock valued at $2,035,000 after acquiring an additional 366 shares during the period. Howard Hughes Medical Institute acquired a brand-new position in shares of Allergan PLC. throughout the 2nd quarter valued at about $103,000. Jacobi Capital Management LLC raised its holdings in shares of Allergan PLC. by 4.9% during the very first quarter. Jacobi Capital Management LLC now owns 472 shares of the company's stock valued at $112,000 after acquiring an additional 22 shares during the duration. JNBA Financial Advisors raised its holdings in shares of Allergan PLC. by 2.5% during the very first quarter. JNBA Financial Advisors now owns 487 shares of the company's stock valued at $116,000 after purchasing an additional 12 shares during the duration. Massey Quick & & Co. LLC raised its holdings in shares of Allergan PLC. by 334.8% during the 2nd quarter. Massey Quick & & Co. LLC now owns 500 shares of the business's stock valued at $122,000 after purchasing an extra 385 shares during the duration. Institutional investors and hedge funds own 82.04% of the business's stock.
COPYRIGHT OFFENSE CAUTION: "Allergan PLC. (AGN) Position Cut by FTB Advisors Inc." was published by Ticker Report and is owned by of Ticker Report. If you are seeing this report on another website, it was unlawfully copied and republished in offense of United States and international copyright & & hallmark legislation. The proper version of this report can be read at https://www.tickerreport.com/banking-finance/2959900/allergan-plc-agn-position-cut-by-ftb-advisors-inc.html.
A number of equities experts have just recently weighed in on the stock. Piper Jaffray Companies set a $227.00 rate objective on shares of Allergan PLC. and gave the business a "hold" ranking in a report on Friday. UBS AG reiterated an "outperform" rating and set a $275.00 cost goal on shares of Allergan PLC. in a report on Wednesday, August 9th. BidaskClub reduced shares of Allergan PLC. from a "buy" rating to a "hold" rating in a report on Wednesday, August 9th. Wells Fargo & & Business repeated an "outperform" ranking and set a $280.00 price goal (up formerly from $270.00) on shares of Allergan PLC. in a report on Wednesday, August 9th. Lastly, Barclays PLC restated an "equal weight" rating on shares of Allergan PLC. in a report on Monday, October 2nd. One equities research analyst has actually ranked the stock with a sell score, 8 have actually designated a hold ranking and fourteen have given a buy rating to the company. Allergan PLC. has an average rating of "Buy" and an agreement target price of $271.44.
Shares of Allergan PLC. ( NYSE AGN)opened at 205.52 on Friday. The company has a market capitalization of $68.71 billion, a P/E ratio of 6.26 and a beta of 1.15. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The firm has a 50-day moving average of $215.92 and a 200-day moving average of $232.05.
Allergan PLC. (NYSE: AGN) last released its incomes results on Thursday, August 3rd. The company reported $4.02 revenues per share (EPS) for the quarter, topping the consensus quote of $3.95 by $0.07. The business had profits of $4.01 billion throughout the quarter, compared to analysts' expectations of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The business's profits for the quarter was up 8.8% compared with the very same quarter last year. During the exact same period in the previous year, the company made $3.35 incomes per share. Usually, equities experts anticipate that Allergan PLC. will post $16.21 revenues per share for the present year.
The business also just recently announced a quarterly dividend, which was paid on Friday, September 15th. Shareholders of record on Friday, August 18th were issued a $0.70 dividend. The ex-dividend date was Wednesday, August 16th. This represents a $2.80 annualized dividend and a yield of 1.36%. Allergan PLC.'s dividend payment ratio (DPR) is currently 9.95%.
Allergan PLC. declared that its Board of Directors has initiated a stock redeemed program on Monday, September 25th that permits the business to buy $2.00 billion in shares. This bought authorization allows the company to purchase up to 2.8% of its shares through open market purchases. Shares redeemed programs are normally an indication that the company's board thinks its shares are undervalued.
About Allergan PLC.Allergan, Inc
is a multi-specialty healthcare business. The Business focuses on developing and advertising pharmaceuticals, biologics, medical devices and over the counter (OTC) items. It discovers, establishes and advertises a variety of products for the ophthalmic, neurological, medical looks, medical dermatology, breast looks, urological and other specialty markets.Receive News & Rankings
for Allergan PLC. Daily-Enter your email address listed below to get a concise day-to-day summary of the current news and experts'ratings for Allergan PLC. and associated business with< a href=https://www.tickerreport.com/daily-email-updates-basic/?symbol=NYSE:AGN&c=Allergan+PLC. > MarketBeat.com's FREE day-to-day email newsletter.